We performed a retrospective analysis of all patients at our institution with confirmed CLL/SLL between 01/01/2010 and 02/14/2019. Patients with CLL/SLL were then evaluated for RT by reviewing clinical documentation and pathologic data in the electronic medical record. We collected baseline demographic, clinical, laboratory, pathology, and outcomes data on patients with CLL/SLL and subsequent DLBCL and who had CMA performed on both the CLL/SLL and DLBCL samples. One patient did exhibit transformation to Hodgkin Lymphoma; however, CMA data was not available on both samples thus was excluded.
CMA was performed using the Infinium HD Human Omni1 BeadChip or the CytoSNP-850 K v1.1 BeadChip Array (Illumina, Inc., San Diego, CA) on genomic DNA extracted from peripheral blood/marrow and fresh or formalin fixed paraffin-embedded (FFPE) lymph node samples. Copy number and genotype data were analyzed using NxClinical software (BioDiscovery, El Segundo, CA). Aberrations that were in 100% of cells and were present in public databases of germline variants were considered constitutional and not included in analysis; whereas, aberrations found in less than 100% of cells were considered clonal changes. Genome build hg19 (February 2009) was used for probe locations and data interpretation.
CMA was performed using the Infinium HD Human Omni1 BeadChip or the CytoSNP-850 K v1.1 BeadChip Array (Illumina, Inc., San Diego, CA) on genomic DNA extracted from peripheral blood/marrow and fresh or formalin fixed paraffin-embedded (FFPE) lymph node samples. Copy number and genotype data were analyzed using NxClinical software (BioDiscovery, El Segundo, CA). Aberrations that were in 100% of cells and were present in public databases of germline variants were considered constitutional and not included in analysis; whereas, aberrations found in less than 100% of cells were considered clonal changes. Genome build hg19 (February 2009) was used for probe locations and data interpretation.